Key result
New oral anticoagulants (dabigatran and rivaroxaban) appear as effective and safe as standard treatment for pulmonary embolism, allowing simplified oral therapy without laboratory monitoring.
Why the study?
Do new oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) provide effective and safe treatment for pulmonary embolism compared to standard parenteral anticoagulants and vitamin K antagonists?
Do new oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) provide effective and safe treatment for pulmonary embolism compared to standard parenteral anticoagulants and vitamin K antagonists?
New oral anticoagulants offer the possibility of greatly simplifying the treatment of PE patients by providing an oral option that does not require laboratory monitoring.
May support simplified oral anticoagulation for PE without monitoring; leaves open prospective validation across all NOACs.
SUMMARY: Therapeutic strategies for most patients with pulmonary embolism (PE) include the administration of low-molecular-weight heparin, fondaparinux or unfractionated heparin, followed by vitamin K antagonists. Over the last few years, research has focused on the development of new oral anticoagulant drugs that could overcome some of the main limitations of available parenteral anticoagulants or vitamin K antagonists. These drugs (e.g., dabigatran, rivaroxaban, apixaban or edoxaban) have been compared with standard treatment in a number of Phase III clinical trials in different clinical settings, including the treatment of acute deep-vein thrombosis and PE. The results of the completed trials with dabigatran and rivaroxaban suggest that both compounds can at least be as effective and safe as the standard treatment in these patients. Thus, there is now the possibility of greatly simplifying the treatment of PE patients with drugs that are administered orally and do not require laboratory monitoring. Thi...
No takes yet. Share an insight, caveat, or question.
Donadini et al. (2012) conducted a review in pulmonary embolism. New oral anticoagulant drugs (dabigatran, rivaroxaban, apixaban, edoxaban) vs. standard treatment was evaluated. New oral anticoagulants (dabigatran and rivaroxaban) appear as effective and safe as standard treatment for pulmonary embolism, allowing simplified oral therapy without laboratory monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: